Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Otlertuzumab |
Trade Name | |
Synonyms | TRU-016|TRU016|TRU 016 |
Drug Descriptions |
Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490, PMID: 27977057). |
DrugClasses | CD37 Antibody 8 |
CAS Registry Number | 1372645-37-8 |
NCIT ID | C74006 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bendamustine + Otlertuzumab | Bendamustine Otlertuzumab | 0 | 1 |
Ibrutinib + Otlertuzumab | Ibrutinib Otlertuzumab | 0 | 1 |
Idelalisib + Otlertuzumab + Rituximab | Idelalisib Otlertuzumab Rituximab | 0 | 1 |
Obinutuzumab + Otlertuzumab | Obinutuzumab Otlertuzumab | 0 | 1 |
Otlertuzumab | Otlertuzumab | 0 | 0 |
Otlertuzumab + Rituximab | Otlertuzumab Rituximab | 0 | 1 |